开发硫化捐赠的乙烯衍生物,通过改善肠道L细胞功能,具有缓解2型糖尿病的效果
Haonan Li1,2, Qingyinglu Ma1,2, Xu Li3
1Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, P. R. China.
Journal of medicinal chemistry
|August 4, 2025
概括
一种新的硫化 (H2S) 捐赠西利宾衍生物,bin-4,有效降低血糖并增强2型糖尿病 (T2DM) 中的胰岛素分泌. 这种基于气体递质的药物通过提高GLP-1水平,对T2DM治疗具有前景.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 2型糖尿病 (T2DM) 与硫化 (H2S) 水平降低有关.
- H2S捐赠者刺激葡萄糖类-1 (GLP-1) 的分泌,这表明T2DM的治疗策略.
- 西利宾衍生品bin-4被开发为一种H2S捐赠的气传递剂药物.
研究的目的:
- 研究bin-4在治疗T2DM中的疗效和机制.
- 为了评估bin-4对GLP-1分泌,葡萄糖平衡和胰岛素分泌的影响.
- 在T2DM小鼠模型中评估bin-4的安全性和代谢概况.
主要方法:
- 研究了bin-4对PI3K/AKT/GSK-3β通路和GLUTag细胞中Nrf2核转位的影响.
- 评估了bin-4激活雌激素受体α和增强GLP-1分泌的能力.
- 在T2DM小鼠中评估了bin-4在降低血糖和提高胰岛素和GLP-1水平的体内功效.
- 确定了毒性概况,并确定了bin-4的潜在代谢物.
主要成果:
- 比因-4提高PI3K/AKT/GSK-3β通路的调节,促进Nrf2转位以抑制氧化损伤和亡.
- 通过雌激素受体α激活,Bin-4增加了30%的GLP-1分泌.
- 在T2DM小鼠中,bin-4降低了63.1%的血糖,增加了90.2%的胰岛素分泌,并增加了91.2%的GLP-1产量.
- 在T2DM小鼠中,Bin-4呈现出可接受的毒性概况.
结论:
- 在T2DM中,Bin-4显示出强大的降血糖和胰岛素敏感作用.
- 该机制涉及H2S捐赠,PI3K/AKT/GSK-3β通路调节和GLP-1增强.
- 对于T2DM管理,Bin-4代表了一个有前途的基于气传递物的治疗候选者.
相关概念视频
Oral Hypoglycemic Agents: Sulfonylureas
332
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
332
Insulin: Biosynthesis, Chemistry, and Preparation
543
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
543
Oral Hypoglycemic Agents: Biguanides and Glitazones
298
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
298
Glucagon-like Receptor Agonists
419
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
419
Diabetes Mellitus: Overview and Type I Subtype
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K
Dipeptidyl Peptidase 4 Inhibitors
260
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
260

